Anti-CPT1A Antibody, clone 2N14 ZooMAb^® Rabbit Monoclonal

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Carnitine O-palmitoyltransferase 1, liver isoform (UniProt: P50416; also known as EC:2.3.1.21, CPT1-L;Carnitine O-palmitoyltransferase I, liver isoform (CPT I; CPTI-L), Carnitine palmitoyltransferase 1A, Succinyltransferase CPT1A) is encoded by the CPT1A (also known as CPT1) gene (Gene ID: 1374) in human. Carnitine O-palmitoyltransferase 1A (CPT1A) is a mitochondrial enzyme that plays a pivotal role in long-chain fatty acid oxidation by catalyzing the conversion of acyl-CoA to acylcarnitine, enabling their transport into the mitochondrial matrix for β-oxidation. CPT1A is an integral membrane protein localized to the outer mitochondrial membrane, where it functions as the rate-limiting step in fatty acid transport. CPT1A contains a catalytic C-terminal domain and a regulatory N-terminal domain that modulates its sensitivity to malonyl-CoA, an allosteric inhibitor derived from glucose metabolism. This sensitivity is influenced by oligomerization states and membrane composition. CPT1A is predominantly expressed in lipogenic tissues such as the liver, but it is also found in the spleen, kidneys, lungs, pancreas, and brain. It is essential for maintaining energy homeostasis, particularly during fasting or metabolic stress conditions. CPT1A interacts carnitine-acylcarnitine translocase and CPT2, forming a cooperative system for mitochondrial fatty acid metabolism. Dysregulation or deficiency of CPT1A has been implicated in metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), hepatic ischemia-reperfusion injury, and insulin resistance. Pathogenic mutations in the CPT1A gene are associated with CPT1A deficiency, a rare autosomal recessive disorder characterized by hypoketotic hypoglycemia, hepatic encephalopathy, and fasting intolerance. Additionally, CPT1A-mediated fatty acid oxidation has been linked to cancer cell survival and resistance to metabolic stress, suggesting its potential as a therapeutic target in oncology. CPT1A′s role in regulating lipid metabolism underscores its importance in both normal physiology and disease pathogenesis. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.

KLH-conjugated linear peptide corresponding to 23 amino acids from the internal region of human CPT1A.

Quality Control Testing

Evaluated by Western Blotting in HeLa cell lysate.

Western Blotting Analysis: A 1:10,000 dilution of this antibody detected CPT1A in HeLa cell lysate.

Tested Applications

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected CPT1A in human liver tissue lysate and a 1:10,000 dilution from in human kidney tissue lysate.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected CPT1A in human kidney tissue sections.

Flow Cytometry Analysis: 1 µg from a representative lot detected CPT1A in one million HeLa cells.

Immunocytochemistry Analysis: A 1:1,000 dilution from a representative lot detected CPT1A in HeLa cells.

Note: Actual optimal working dilutions must be determined by end user as specimens and experimental conditions may vary with the end user.

Clone 2N14 is a ZooMAb^® rabbit recombinant monoclonal antibody that detects CPT1A. It targets an epitope within 23 amino acids from the internal region.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.